Wesbanco Bank Inc. Has $4.43 Million Stock Position in Pfizer Inc. $PFE

Wesbanco Bank Inc. lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 13.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 177,905 shares of the biopharmaceutical company’s stock after selling 28,166 shares during the quarter. Wesbanco Bank Inc.’s holdings in Pfizer were worth $4,430,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of PFE. Horizon Financial Services LLC boosted its position in Pfizer by 174.8% during the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 645 shares during the last quarter. YANKCOM Partnership bought a new stake in shares of Pfizer during the 4th quarter worth approximately $28,000. Grey Fox Wealth Advisors LLC bought a new stake in shares of Pfizer during the 3rd quarter worth approximately $29,000. Darwin Wealth Management LLC bought a new stake in shares of Pfizer during the 2nd quarter worth approximately $32,000. Finally, Torren Management LLC bought a new stake in shares of Pfizer during the 4th quarter worth approximately $34,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on PFE. UBS Group upped their price objective on Pfizer from $25.00 to $27.00 and gave the stock a “neutral” rating in a research note on Monday, April 13th. Zacks Research upgraded Pfizer from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. Morgan Stanley upped their price objective on Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a research note on Friday, April 10th. Daiwa Securities Group cut Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price objective on the stock. in a research note on Thursday, February 12th. Finally, Guggenheim upped their price objective on Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a research note on Tuesday, March 24th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, twelve have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and a consensus price target of $28.74.

Pfizer Stock Down 3.1%

PFE stock opened at $25.65 on Friday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.87. The stock has a market capitalization of $146.17 billion, a price-to-earnings ratio of 19.58 and a beta of 0.35. The business’s fifty day moving average price is $27.14 and its two-hundred day moving average price is $26.16. Pfizer Inc. has a fifty-two week low of $21.97 and a fifty-two week high of $28.75.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. The firm had revenue of $14.45 billion for the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter last year, the business earned $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities analysts anticipate that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, May 8th. This represents a $1.72 annualized dividend and a yield of 6.7%. Pfizer’s dividend payout ratio (DPR) is presently 131.30%.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Scotiabank initiated a Buy view on Pfizer, adding to recent analyst confidence in the stock. Pfizer (PFE) Receives a Buy from Scotiabank
• Positive Sentiment: Erste Group slightly raised its FY2026 EPS estimate for Pfizer, reinforcing expectations that earnings remain stable and in line with consensus.
• Positive Sentiment: Recent coverage highlighted Pfizer’s Q1 beat, better-than-expected sales, and progress in its oncology pipeline, suggesting the company’s newer drugs are becoming more important to the investment story. How Pfizer’s Q1 Beat, Oncology Wins and Patent Deals At Pfizer (PFE) Has Changed Its Investment Story
• Positive Sentiment: Pfizer’s dividend remains a major draw for income investors, and a recent article argued that the high yield is still supported by management’s execution and cash flow. Pfizer’s 6.5% Dividend Yield Looked Too Good to Be True — but Management Just Silenced the Skeptics
• Neutral Sentiment: Pfizer is continuing to advance a new Phase 1 cancer trial, which signals ongoing investment in oncology but is still too early to materially change near-term financial results. Pfizer’s New Phase 1 Cancer Trial Signals Fresh Oncology Push for PFE Investors
• Neutral Sentiment: Pfizer was also mentioned in a cancer-care industry recognition announcement, but the item is mostly reputational and unlikely to move the stock on its own.
• Negative Sentiment: Pfizer halted an early-stage cancer study, and investors may view the termination as a small setback for its oncology pipeline, even if the financial impact is limited. Pfizer Terminates Early-Stage Cancer Trial: What It Means for PFE Investors
• Negative Sentiment: Pfizer ended another early-stage lymphoma combination trial, which adds to concerns that some pipeline programs may not advance as hoped. Pfizer Ends Early-Stage Lymphoma Combo Trial, Trimming a Small Piece of Its Oncology Upside

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.